GSK126 | GSK2816126A | EZH2 Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / GSK126

GSK126 {[allProObj[0].p_purity_real_show]}

货号：A114568 同义名： GSK2816126A;GSK2816126

GSK126 is a potent, highly selective EZH2 methyltransferase inhibitor with IC50 of 9.9 nM, > 1000-fold selective for EZH2 over 20 other human methyltransferases.

GSK126 化学结构
CAS号：1346574-57-9

GSK126 3D分子结构
CAS号：1346574-57-9

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

GSK126 纯度/质量文件产品仅供科研

货号：A114568 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JACS Au, 2024. Ambeed. [ A148168 ]; • JMC, 2024. Ambeed. [ A187643 ]; • JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]; • Biomacromolecules, 2024. Ambeed. [ A110759 ]; • Biomacromolecules, 2024. Ambeed. [ A203543 ]; 更多 >

表观遗传阅读框亚型比较
组蛋白甲基转移酶亚型比较

产品名称	BET ↓ ↑	bromodomain ↓ ↑	BRPF ↓ ↑	CBP/beta-catenin ↓ ↑	p300/CBP ↓ ↑	其他靶点	纯度
MS436	++ BRD4 (1), Ki: <0.085 μM BRD4 (2), Ki: 0.34 μM						{[allProObj[0].p_purity_real_show]}
CPI-203	+++ BRD4, IC50: 37 nM						{[allProObj[0].p_purity_real_show]}
GSK1324726A	+++ BRD4, IC50: 22 nM BRD2, IC50: 31 nM						{[allProObj[0].p_purity_real_show]}
PFI-1	++ BRD4, IC50: 0.22 μM BRD2, IC50: 98 nM						{[allProObj[0].p_purity_real_show]}
Apabetalone	+ BD2, IC50: 0.51 μM						{[allProObj[0].p_purity_real_show]}
(+)-JQ1	+++ BRD4 (2), IC50: 33 nM BRD4 (1), IC50: 77 nM						{[allProObj[0].p_purity_real_show]}
I-BET151	+ BRD4, IC50: 0.5 μM BRD3, IC50: 0.25 μM						{[allProObj[0].p_purity_real_show]}
Molibresib	+++ BET proteins, IC50: 35 nM						{[allProObj[0].p_purity_real_show]}
I-BRD9	+++ BRD9, pIC50: 7.3 BRD4, pIC50: 5.3						{[allProObj[0].p_purity_real_show]}
BI-7273	++++ BRD7, IC50: 117 nM BRD9, IC50: 19 nM						{[allProObj[0].p_purity_real_show]}
Pelabresib	+++ BRD4-BD1, IC50: 39 nM						{[allProObj[0].p_purity_real_show]}
ARV-825	+++ BRD4 BD2, Kd: 28 nM BRD4 BD1, Kd: 90 nM						{[allProObj[0].p_purity_real_show]}
Birabresib							{[allProObj[0].p_purity_real_show]}
BI 2536	+++ BRD4, Kd: 37 nM					c-Myc	{[allProObj[0].p_purity_real_show]}
Bromosporine	++ BRD2, IC50: 0.29 μM BRD9, IC50: 0.122 μM	++++ CECR2, IC50: 17 nM					{[allProObj[0].p_purity_real_show]}
XMD8-92	++ BRD4 (1), Kd: 170 nM						{[allProObj[0].p_purity_real_show]}
Mivebresib	✔						{[allProObj[0].p_purity_real_show]}
BI-9564	++++ BRD9, Kd: 5.9 nM BRD7, Kd: 73 nM	++ CECR2, Kd: 77 nM					{[allProObj[0].p_purity_real_show]}
AZD5153 6-Hydroxy-2-naphthoic acid	++++ FL-BRD4, IC50: 5 nM						{[allProObj[0].p_purity_real_show]}
PLX51107	++++ BRD4 BD2, Kd: 1.7 nM BRD3 BD1, Kd: 2.1 nM						{[allProObj[0].p_purity_real_show]}
FL-411	+ BRD4(1), IC50: 0.43 μM						{[allProObj[0].p_purity_real_show]}
ABBV-744	✔						{[allProObj[0].p_purity_real_show]}
dBET6	++++ BRD4, IC50: 14 nM						{[allProObj[0].p_purity_real_show]}
dBET1	++++ BRD4, IC50: 20 nM						{[allProObj[0].p_purity_real_show]}
MZ1	++++ Brd3(BD2), Kd: 13 nM Brd2(BD2), Kd: 62 nM						{[allProObj[0].p_purity_real_show]}
dBET57	+ BRD4_BD1, DC50: 500 nM						{[allProObj[0].p_purity_real_show]}
SF2523	+ BRD4, IC50: 241 nM					DNA-PK	{[allProObj[0].p_purity_real_show]}
INCB054329	++++ BRD3-BD1, IC50: 9 nM BRD4-BD1, IC50: 119 nM						{[allProObj[0].p_purity_real_show]}
INCB-057643	✔						{[allProObj[0].p_purity_real_show]}
(E/Z)-ZL0420	+++ BRD4 BD1, IC50: 27 nM BRD4 BD2, IC50: 32 nM						{[allProObj[0].p_purity_real_show]}
BMS-986158	✔						{[allProObj[0].p_purity_real_show]}
BRD4 Inhibitor-10	++++ BRD4-BD2, IC50: 41 nM BRD4-BD1, IC50: 5 nM						{[allProObj[0].p_purity_real_show]}
A1874	✔						{[allProObj[0].p_purity_real_show]}
Y06036	++ BRD4 (1), Kd: 82 nM						{[allProObj[0].p_purity_real_show]}
Alobresib	✔					NF-κB	{[allProObj[0].p_purity_real_show]}
ODM-207	✔						{[allProObj[0].p_purity_real_show]}
GSK778	+++ BRD2-BD1, IC50: 75nM BRD4-BD1, IC50: 143 nM						{[allProObj[0].p_purity_real_show]}
SRX3207	+ BRD41, IC50: 3070 nM BRD42, IC50: 3070 nM					Syk	{[allProObj[0].p_purity_real_show]}
GSK046	+++ BRD4_BD2, IC50: 214 nM BRD3_BD2, IC50: 98 nM						{[allProObj[0].p_purity_real_show]}
GSK620	✔						{[allProObj[0].p_purity_real_show]}
Thalidomide-NH-C4-NH-Boc	✔						{[allProObj[0].p_purity_real_show]}
Trotabresib	✔						{[allProObj[0].p_purity_real_show]}
NHWD-870	✔						{[allProObj[0].p_purity_real_show]}
CFT8634	++++ BRD9, DC50: 3 nM						{[allProObj[0].p_purity_real_show]}
GSK2801		++ BAZ2B, Kd: 136 nM BAZ2A, Kd: 257 nM					{[allProObj[0].p_purity_real_show]}
KG-501		✔					{[allProObj[0].p_purity_real_show]}
UNC 669		+ L3MBTL4, IC50: 6 μM L3MBTL3, IC50: 35 μM					{[allProObj[0].p_purity_real_show]}
PFI-3		+++ SMARCA4, Kd: 55 nM SMARCA2A, Kd: 72 nM					{[allProObj[0].p_purity_real_show]}
UNC1215		+++ L3MBTL3, IC50: 120 nM L3MBTL3- D274A, IC50: 3.5 μM					{[allProObj[0].p_purity_real_show]}
EED226		++ EED, Kd: 82 nM PRC2, Kd: 114 nM					{[allProObj[0].p_purity_real_show]}
BRD9539		✔					{[allProObj[0].p_purity_real_show]}
UNC926		+ L3MBTL1, Kd: 3.9 μM					{[allProObj[0].p_purity_real_show]}
666-15		++ CREB, IC50: 81 nM					{[allProObj[0].p_purity_real_show]}
UNC6852		+ EED, IC50: 247 nM					{[allProObj[0].p_purity_real_show]}
BAZ1A-IN-1		+ BAZ1A, Kd: 0.52 μM					{[allProObj[0].p_purity_real_show]}
PFI-4			++ BRPF1, IC50: 80 nM BRPF2, IC50: 7.9 μM				{[allProObj[0].p_purity_real_show]}
OF-1			++ BRPF2, Kd: 500 nM BRPF1B, Kd: 100 nM				{[allProObj[0].p_purity_real_show]}
GSK-5959			++ BRPF3, pIC50: 7.1 BRPF2, pIC50: 5.2				{[allProObj[0].p_purity_real_show]}
GSK6853			++++ BRPF1, pIC50: 8.1				{[allProObj[0].p_purity_real_show]}
NI-42			++++ BRPF1, IC50: 48 nM BRPF3, IC50: 260 nM				{[allProObj[0].p_purity_real_show]}
E-7386				+++ CBP/beta-catenin, IC50: 0.0484 μM			{[allProObj[0].p_purity_real_show]}
I-CBP112					++ p300, Kd: 167 nM CBP, Kd: 151 nM		{[allProObj[0].p_purity_real_show]}
Histone Acetyltransferase Inhibitor II					+ p300, IC50: 5 μM		{[allProObj[0].p_purity_real_show]}
C646					+ p300/CBP, Ki: 400 nM		{[allProObj[0].p_purity_real_show]}
Anacardic Acid					+ p300/CBP, IC50: 8.5 μM PCAF, IC50: 5 μM		{[allProObj[0].p_purity_real_show]}
SGC-CBP30					++++ CREBBP, IC50: 21 nM EP300, IC50: 38 nM		{[allProObj[0].p_purity_real_show]}
Nordihydroguaiaretic acid					✔	HER2,IGF-1R	{[allProObj[0].p_purity_real_show]}
Curcumin					+ p300, IC50: ~25 μM	Nrf2,Ferroptosis,NF-κB	{[allProObj[0].p_purity_real_show]}
PF-CBP1 HCl					++ CREBBP, IC50: 125nM p300/CBP, IC50: 363nM		{[allProObj[0].p_purity_real_show]}
CPI-637					+++ CBP, IC50: 0.03 μM EP300, IC50: 0.051 μM		{[allProObj[0].p_purity_real_show]}
Foscenvivint					✔	β-catenin	{[allProObj[0].p_purity_real_show]}
A-485					++ p300 HAT, IC50: 0.06 μM		{[allProObj[0].p_purity_real_show]}
GNE-781	+ BRD4(1), IC50: 5100 nM				++++ CBP, IC50: 0.94 nM		{[allProObj[0].p_purity_real_show]}
NEO2734	+++ BET, IC50: <30 nM				+++ p300/CBP, IC50: <30 nM		{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	Histone Methyltransferase ↓ ↑	纯度
BRD4770	✔	{[allProObj[0].p_purity_real_show]}
UNC1999	+++ EZH1, IC50: 45 nM EZH2, IC50: 2 nM	{[allProObj[0].p_purity_real_show]}
EPZ005687	++ EZH2, Ki: 24 nM	{[allProObj[0].p_purity_real_show]}
EPZ015666	+++ PRMT5, Ki: 5 nM	{[allProObj[0].p_purity_real_show]}
3-Deazaneplanocin A HCl	++++ S-adenosylhomocysteine hydrolase, Ki: 50 pM	{[allProObj[0].p_purity_real_show]}
EPZ6438	+++ EZH2, Ki: 2.5 nM EZH2, IC50: 11 nM	{[allProObj[0].p_purity_real_show]}
GSK126	++ EZH2, IC50: 9.9 nM	{[allProObj[0].p_purity_real_show]}
MI-3	+ Menin-MLL, IC50: 648 nM	{[allProObj[0].p_purity_real_show]}
MM-102	++ MLL1, IC50: 0.4 μM	{[allProObj[0].p_purity_real_show]}
EI1	++ Ezh2 (wild-type), IC50: 15 nM EZH2 (Y641F), IC50: 13 nM	{[allProObj[0].p_purity_real_show]}
SGC0946	++++ DOT1L, IC50: 0.3 nM	{[allProObj[0].p_purity_real_show]}
PFI-2 HCl	++++ SETD7, Ki: 0.33 nM SETD7, IC50: 2 nM	{[allProObj[0].p_purity_real_show]}
Pinometostat	++++ DOT1L, Ki: 80 pM	{[allProObj[0].p_purity_real_show]}
EPZ004777	+++ DOT1L, IC50: 0.4 nM	{[allProObj[0].p_purity_real_show]}
Entacapone	++ COMT, IC50: 151 nM	{[allProObj[0].p_purity_real_show]}
UNC0379	+ SETD8, IC50: 7.9 μM	{[allProObj[0].p_purity_real_show]}
Menin-MLL inhibitor MI-2	+ Menin-MLL, IC50: 446 nM	{[allProObj[0].p_purity_real_show]}
GSK343	+++ EZH1, IC50: 240 nM EZH2, IC50: 4 nM	{[allProObj[0].p_purity_real_show]}
BIX-01294 3HCl	+ G9a, IC50: 2.7 μM	{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

GSK126 生物活性

靶点	Histone Methyltransferase EZH2, IC50:9.9 nM
描述	EZH2 is the enzymatic subunit of PRC2 (Polycomb repressive complex 2), a complex that can methylate lysine 27 of histone H3 (H3K27) to promote transcriptional silencing. GSK126 is a potent inhibitor of EZH2 and inhibits both wild-type and mutant EZH2 methyltransferase activity with similar potencies (Ki^app=0.5 - 3 nM, measure by enzymatic activity) and has more than 1,000-fold selectivity for EZH2 as compared with other methyltransferases and 150-fold as compared to EZH1 (Ki^app = 89 nM). GSK126 induced a 50% loss of H3K27me3 in both EZH2 wild-type and mutant DLBCL cell lines at concentrations ranging from 7 - 252 nM independent of EZH2 mutation status (treated with GSK126 for 48h). GSK126 most potently inhibited H3K27me3, followed by H3K27me2 and H3K27me1 were only weakly reduced at the highest inhibitor concentration, with no effect on total histone H3 and PRC2 components. Following 10 days of once-daily dosing of GSK126 in mice using subcutaneous xenografts of KARPAS-422 and Pfeiffer cells, on dose 15 - 150 mg/kg, global H3K27me3 decreased and EZH2 targeted genes (TXNIP and TNFRSF21) expression increased in a dose dependent fashion. With daily 50 mg/kg dosing, complete tumor growth inhibition can be observed in both KARPAS-422 and Pfeiffer cell models. Complete tumor eradication can be observed on dose of 150 mg/kg daily or 300 mg/kg twice a week^[1].
作用机制	GSK126 is the SAM-competitive inhibitor of PRC2^[1].

GSK126 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
human A549 cells		Cytotoxic assay	72 h	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by WST-1 assay, GI50=18.7 μM.	24767850
human Daudi cells		Cytotoxic assay	72 h	Cytotoxicity against human Daudi cells assessed as growth inhibition after 72 hrs by WST-1 assay, GI50=11.2 μM.	24767850
human HeLa cells		Function assay	72 h	Inhibition of EZH2 in human HeLa cells assessed as reduction in H3K27me3 levels incubated for 72 hrs by ELISA method, IC50=0.28 μM.	26189078
human PC3 cells		Cytotoxic assay	72 h	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by WST-1 assay, GI50=9.4 μM.	24767850

GSK126 动物研究

Dose

Mice: 2.5 mg/kg^[2] (i.v.); min = 125 mg/kg, max = 1000 mg/kg^[3] (p.o.)

Administration

i.v., p.o.

Pharmacokinetics

Animal	Rats^[4]
Dose	50 mg/kg
Administration	p.o.
C_max	155.6 ± 42.4 ng/ml
T_max	0.25 h
AUC_0→∞	636.3 ± 82.0 h·ng/ml
T_β	10.7 ± 3.2 h

GSK126 参考文献

[1]McCabe MT, Ott HM, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012 Dec 6;492(7427):108-12.

[2]Zhang P, de Gooijer MC, et al. ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors. Int J Cancer. 2015 Oct 15;137(8):2007-18.

[3]Campbell JE, Kuntz KW, et al. EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. ACS Med Chem Lett. 2015 Mar 4;6(5):491-5.

[4]EZH2 Inhibitor GSK126: Metabolism, drug transporter and rat pharmacokinetic studies

GSK126 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.49mL

1.90mL

0.95mL

18.99mL

3.80mL

1.90mL

GSK126 技术信息

CAS号	1346574-57-9
分子式	C₃₁H₃₈N₆O₂
分子量	526.672

别名	GSK2816126A;GSK2816126
运输	蓝冰

存储条件

粉末 Keep in dark place,Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 12 mg/mL(22.78 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

IP 5% DMSO+water 0.8 mg/mL clear

PO 0.5% CMC-Na 48 mg/mL suspension

GSK126 {[allProObj[0].p_purity_real_show]}

GSK126 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

GSK126 质控信息

GSK126 生物活性

GSK126 细胞研究

GSK126 动物研究

GSK126 参考文献

GSK126 实验方案

GSK126 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

GSK126 {[allProObj[0].p_purity_real_show]}

GSK126 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

GSK126 质控信息

GSK126 生物活性

GSK126 细胞研究

GSK126 动物研究

GSK126 参考文献

GSK126 实验方案

GSK126 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

GSK126 纯度/质量文件产品仅供科研